Sol-Gel reports Q2 2026 results, SGT-610 Phase 3 readout on track for late November
Trial dropout rate is running lower than expected as Sol-Gel advances new studies in high-frequency BCC and Mohs surgery neo-adjuvant use.
Sol-Gel Technologies reported financial results for the second quarter of 2026 and gave a corporate update on August 20, 2026.
The company's pivotal Phase 3 trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome is continuing to progress. So far, 10 of the 113 enrolled patients have dropped out, a rate of 9 percent that is lower than the company originally expected. Last patient last visit is expected in September 2026, with top-line results scheduled for late November 2026.1
Beyond the Gorlin program, Sol-Gel started a proof-of-concept study looking at how safe and effective patidegib gel is in patients without Gorlin syndrome who have high-frequency basal cell carcinoma (HF-BCC), with enrollment expected to start in early October 2026.1 The study plans to enroll about 20 subjects aged 18 and older with facial, head, and neck HF-BCC, assessing safety and efficacy after twice-daily application for up to 12 months.1 Results are meant to help inform a planned pivotal registration study, currently expected in late 2027 or the first half of 2028.1
Separately, prompted by physicians already using oral hedgehog inhibitors off-label ahead of Mohs surgery, Sol-Gel has begun a small study testing topical patidegib as a neo-adjuvant treatment before BCC surgery, with enrollment expected to begin in October 2026.1
The company also disclosed a provisional patent filing for an injectable hedgehog inhibitor treatment delivered directly into odontogenic keratocysts (OKC), a serious complication of Gorlin syndrome that affects the jaw and occurs about as often as BCC does in these patients.1
On financials, second-quarter revenue was $0.6 million, down from $17.3 million a year earlier, mainly because the prior-year period included $16.7 million from an IP sale to Mayne.1 Net loss was $3.7 million, or $1.13 per share, versus net income of $11.6 million, or $4.17 per share, in the same quarter of 2025.1 Sol-Gel held $49.3 million in cash, deposits, and marketable securities as of June 30, 2026, which it expects will fund operations into the first quarter of 2028.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.